BCTX vs. KALA, CNTB, CELU, XLO, DYAI, ALVR, ATRA, OSTX, OVID, and NBRV
Should you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include KALA BIO (KALA), Connect Biopharma (CNTB), Celularity (CELU), Xilio Therapeutics (XLO), Dyadic International (DYAI), AlloVir (ALVR), Atara Biotherapeutics (ATRA), OS Therapies (OSTX), Ovid Therapeutics (OVID), and Nabriva Therapeutics (NBRV). These companies are all part of the "pharmaceutical products" industry.
BriaCell Therapeutics vs.
KALA BIO (NASDAQ:KALA) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.
BriaCell Therapeutics has lower revenue, but higher earnings than KALA BIO. KALA BIO is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, KALA BIO had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for KALA BIO and 0 mentions for BriaCell Therapeutics. BriaCell Therapeutics' average media sentiment score of 1.58 beat KALA BIO's score of 0.15 indicating that BriaCell Therapeutics is being referred to more favorably in the news media.
KALA BIO presently has a consensus target price of $15.00, suggesting a potential upside of 124.05%. BriaCell Therapeutics has a consensus target price of $32.00, suggesting a potential upside of 573.40%. Given BriaCell Therapeutics' higher possible upside, analysts plainly believe BriaCell Therapeutics is more favorable than KALA BIO.
24.6% of KALA BIO shares are held by institutional investors. Comparatively, 15.4% of BriaCell Therapeutics shares are held by institutional investors. 8.3% of KALA BIO shares are held by insiders. Comparatively, 5.7% of BriaCell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
BriaCell Therapeutics' return on equity of 0.00% beat KALA BIO's return on equity.
KALA BIO received 289 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 66.89% of users gave KALA BIO an outperform vote.
KALA BIO has a beta of -2.03, meaning that its stock price is 303% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500.
Summary
KALA BIO beats BriaCell Therapeutics on 8 of the 15 factors compared between the two stocks.
Get BriaCell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BriaCell Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BCTX) was last updated on 2/21/2025 by MarketBeat.com Staff
Free BCTX Stock Alerts